Economic costs associated with an MS relapse

Multiple Sclerosis and Related Disorders

Volumn 3, Issue 6, 2014, Pages 678-683

  O'Connell, K ^a   Kelly, S B ^a   Fogarty, E ^a,b   Duggan, M ^a   Buckley, L ^a   Hutchinson, M ^a   Mcguigan, C ^a   Tubridy, N ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b National Centre for Pharmacoeconomics   (Ireland)

Author keywords

Direct cost; Economic cost; Indirect cost; Multiple sclerosis; Relapse

Indexed keywords

STEROID;

ADULT; AGE; ARTICLE; CHILD CARE; CONSULTATION; CONTROLLED STUDY; COST OF ILLNESS; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; DRUG COST; DRUG USE; EMPLOYMENT STATUS; EXPANDED DISABILITY STATUS SCALE; FEMALE; FINANCE; GENDER; GENERAL PRACTITIONER; HEALTH CARE COST; HOSPITAL COST; HOSPITALIZATION; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MEAL; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; MULTIPLE SCLEROSIS; PRODUCTIVITY; PROSPECTIVE STUDY; QUESTIONNAIRE; RELAPSE; TRAVEL; ECONOMICS; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX;

ADULT; COST OF ILLNESS; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 84928004038     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2014.09.002     Document Type: Article

References (29)

1. Guidelines for the Economic Evaluation of Health Technologies in Ireland, 2010.
2. Confavreux C, Vukusic S. Natural history of multiple sclerosis: A unifying concept. Brain 2006;129:606-16.
3. Dorris DR, Nguyen A, Gieser L, Lockner R, Lublinsky A, Patterson M, et al. Oligodeoxyribonucleotide probe accessibility on a three- dimensional DNA microarray surface and the effect of hybridization time on the accuracy of expression ratios. BMC Biotechnol 2003;3:6.
4. Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 2010;81:907-12.
5. Fogarty E ea. Resource use and economic consequences associated with multiple sclerosis. Mult Scler 2013;19:74-558.
6. Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N. Contribution of relapses to disability in multiple sclerosis. J Neurol 2008;255:280-7.
7. IFNB-MS-Study-Group. Interferon beta-1b is effective in relapsing- remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655-61.
8. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94.
9. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76.
10. Karampampa K, Gustavsson A, Miltenburger C, Eckert B. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler 2012a;18:7-15.
11. Karampampa K, Gustavsson A, Miltenburger C, Kindundu CM, Selchen DH. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: The costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol 2012b;19:e11-e25.
12. Karampampa K, Gustavsson A, van-Munster ET, Hupperts RM, Sanders EA, Mostert J, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in Multiple Sclerosis study: The costs and utilities of MS patients in The Netherlands. J Med Econ 2013;16:939-50.
13. Kobelt G, Texier-Richard B, Lindgren P. The long-term cost of multiple sclerosis in France and potential changes with disease- modifying interventions. Mult Scler 2009;15:741-51.
14. Korchounov A, Tabatadze T, Spivak D, Rossy W, Krasnianski M. MS related employment and disease modifying treatment in the German working population: 1994-2009. NeuroRehabilitation 2014.
15. Krause I, Kern S, Horntrich A, Ziemssen T. Employment status in multiple sclerosis: impact of disease-specific and non-disease- specific factors. Mult Scler 2013;19:1792-9.
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33: 1444-52.
17. Leray E, Yaouanq J, Le-Page E, Coustans M, Laplaud D, Oger J, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010;133:1900-13.
18. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528-32.
19. Noyes K, Bajorska A, Chappel A, Schwid SR, Mehta LR, Weinstock- Guttman B, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: A population-based study. Neurology 2011;77:355-63.
20. O'Brien JA, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003;3:17.
21. Pack TG, Szirony GM, Kushner JD, Bellaw JR. Quality of life and employment in persons with multiple sclerosis. Work 2013.
22. Pan F, Goh JW, Cutter G, Su W, Pleimes D, Wang C. Long-term cost- effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States. Clin Ther 2012;34:1966-76.
23. Parise H, Laliberte F, Lefebvre P, Duh MS, Kim E, Agashivala N, et al. Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. J Neurol Sci 2013;330:71-7.
24. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Switching to second-line therapies in interferon-beta-treated relapsing- remitting multiple sclerosis patients. Eur Neurol 2009;61:177-82.
25. PRISMS. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. (PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group). Lancet 1998;352:1498-504.
26. Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry 2014;85:67-75.
27. Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van-der-Kop ML, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308:247-56.
28. Shirani A, Zhao Y, Karim ME, Petkau J, Gustafson P, Evans C, et al. Investigation of heterogeneity in the association between inter- feron beta and disability progression in multiple sclerosis: An observational study. Eur J Neurol. 2013.
29. Uitdehaag B, Constantinescu C, Cornelisse P, Jeffery D, Kappos L, Li D, et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord 2011;4:3-14.